Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00762476 · ClinicalTrials.gov registry record · Phase 2
Efficacy Trial of 3804-250A in the Prevention of Cold Illnesses
A Phase 2 study of Common Cold, sponsored by The Dial Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 411
- Enrollment target
- 2
- Study locations
NCT00762476: Completed Phase 2 study of Common Cold, sponsored by The Dial Corporation.
NCT00762476 is a Phase 2 study of Common Cold that has completed, run by The Dial Corporation. The registered enrollment target is 411 participants, above the 352-participant average among 5 other Common Cold trials with a reported enrollment target (17% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00762476, a Phase 2 study of Common Cold, has completed, sponsored by The Dial Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 411 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy of 3804-250A in the prevention of the common cold. The study will also evaluate whether 3804-250A prevents rhinovirus infection, a virus that causes many common colds.
Primary Outcome
Comparison of the total number of incidence of cold illnesses over the course of the study per 100 subjects in each treatment group
Conditions Studied
Interventions
- DRUG 3804-250A
- DRUG 3804-291
Study Locations (2)
New Jersey
- TKL Research, Inc. - Paramus
Virginia
- University of Virginia School of Medicine - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 411 participants |
| Start Date | 2008-08 |
| Est. Completion | 2008-11 |
| Phase | Phase 2 |
What the finished NCT00762476 record still lists
NCT00762476 is an interventional study that assigns participants to a tested intervention. The registered 411 participants enrollment target is mid-sized for trials with a published cap, above the 352-participant average among 5 other Common Cold trials with a reported enrollment target (17% higher).
The record links to 1 condition, with Common Cold appearing as the primary indexed condition, and to 2 interventions - of which 3804-250A is the first listed.
NCT00762476 reports a single indexed study location in New Jersey, Virginia.
Frequently Asked Questions
What is clinical trial NCT00762476 about?
NCT00762476 is a clinical study titled "Efficacy Trial of 3804-250A in the Prevention of Cold Illnesses". The purpose of this study is to evaluate the efficacy of 3804-250A in the prevention of the common cold. The study will also evaluate whether 3804-250A prevents rhinovirus infection, a virus that causes many common colds.
What is the current status of trial NCT00762476?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 411 participants. The study started on 2008-08. Estimated completion is 2008-11.
What conditions does trial NCT00762476 study?
This clinical trial studies the following conditions: Common Cold.
What interventions are being tested in trial NCT00762476?
The interventions under investigation include: 3804-250A (DRUG), 3804-291 (DRUG).
Who is sponsoring clinical trial NCT00762476?
This trial is sponsored by The Dial Corporation, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00762476 being conducted?
This trial has 2 study locations across New Jersey, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Common Cold
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Randomized, Triple-blind, Placebo-controlled Study to Evaluate the Effects of a Throat Spray on the Incidence and Duration of Sickness
ACTIVE NOT RECRUITING · NA
-
Study to Evaluate the Efficacy of EZC Pak in Adults With Upper Respiratory Infection (URI)
COMPLETED · NA
-
A Clinical Evidence Study Evaluating Quality of Life Parameters Following Treatment With Robitussin
COMPLETED · Phase 4
-
Echinacea Versus Placebo Effect in Common Cold (Physician Echinacea Placebo)
COMPLETED · Phase 3
-
Audio Data Collection for Identification and Classification of Coughing
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05993689 · 412 participants · NA
Building TrUst and UNiting Teams Through DouLa partnErship - BUNDLE
- NCT06699212 · 412 participants · Phase 3
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
- NCT02043691 · 410 participants · NA
Evaluation of the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and Surgeon-Modified Endograft in Treating Aortic Pathologies
- NCT03042975 · 410 participants
Imaging Genetics of Laryngeal Dystonia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia